Carregant...
Increased risk of adverse events when changing intravenous immunoglobulin preparations
Intravenous immunoglobulin (IVIG) therapy has represented a major advance in the treatment of patients with primary immune deficiency disorders. In September 2000 a new IVIG formulation, Intragam P, was introduced into clinical use. Intragam P is prepared by delipidation of pooled plasma followed by...
Guardat en:
| Autors principals: | , , |
|---|---|
| Format: | Artigo |
| Idioma: | Inglês |
| Publicat: |
Blackwell Science Inc
2004
|
| Matèries: | |
| Accés en línia: | https://ncbi.nlm.nih.gov/pmc/articles/PMC1809000/ https://ncbi.nlm.nih.gov/pubmed/15030521 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1111/j.1365-2249.2004.02412.x |
| Etiquetes: |
Afegir etiqueta
Sense etiquetes, Sigues el primer a etiquetar aquest registre!
|